Jefferies downgraded EDAP TMS (EDAP) to Hold from Buy with a price target of $2, down from $8. The firm sees downside to consensus estimates. While the company’s high intensity focused ultrasound sales should growth in the mid-teens range, consensus expects higher, leaving numbers too high in the near to mid-term, the analyst tells investors in a research note. Jefferies does not incorporate sales from endometriosis or benign prostatic hyperplasia applications for EDAP TMS, citing regulatory and timeline uncertainty.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDAP:
- EDAP TMS S.A. Earnings Call Highlights HIFU Growth
- EDAP TMS price target lowered to $4.50 from $5 at Piper Sandler
- EDAP TMS Reports Record HIFU Revenue Growth
- Morning Movers: Nvidia slips following report of H20 chip shortage in China
- EDAP TMS Achieves Record HIFU Revenue and Expands Clinical Applications